Business Wire

ALBACORE-CAPITAL-GRP

13.2.2020 11:02:04 CET | Business Wire | Press release

Share
AlbaCore Capital Group Confirms €1.5 Billion AUM1 for AlbaCore Partners II

European credit investment firm AlbaCore Capital Group (“AlbaCore”, “the Firm”), announced the successful close of its second fund, AlbaCore Partners II ICAV (“Fund II”), which has €1.5bn1 in total AUM. The Firm also recently announced plans for a debut CLO in 2020, which is currently in the warehousing phase. AlbaCore’s total AUM now stands at €3.6bn2 across its commingled and customised vehicles. The Firm’s investor base includes pension funds, sovereign wealth funds, endowments, insurance companies, consultants and family office investors, across Europe, North America, Middle East and Asia.

AlbaCore’s strategy focuses on bespoke private credit solutions for larger European companies, with the flexibility to opportunistically invest in secondary and primary markets when relative value is attractive. AlbaCore expects Fund II to be approximately 60% deployed at the end of February, after actively buying in the Q4 2018 credit market sell-off, and more recently shifting focus to primary and private markets. AlbaCore was the sole underwriter for subordinated debt related to two UK public-to-private transactions: BCA Marketplace (LSE: BCA - delisted) and Ei Group (LSE: EIG). Fund II gross IRR for 2019 was +20.6%.3

Bill Ammons, Founding Partner and Portfolio Manager, commented, “Our investing over the past fifteen months demonstrates the value of a flexible mandate in periods of market stress and also periods of resurging positive sentiment, as we saw in the second half of 2019. We are particularly excited about the recent BCA and Stonegate’s acquisition of Ei Group deals, which exemplify AlbaCore’s ability to provide unique, sizeable capital solutions that helped unlock the deals for the sponsor, while also providing an attractive risk/return to our investors.”

AlbaCore has built a 32-person team across its London and Dublin offices, and invests in a capital structure-agnostic manner, via a combination of senior secured loans, high yield bonds, private debt, and preferred equity. AlbaCore’s focus on generating consistent risk-adjusted returns across the capital structure and liquidity spectrum has generated 870bps of gross alpha over European credit markets across its two funds since inception4 .

AlbaCore champions a dynamic ESG approach which is well-integrated into the team’s investment decision making and ongoing risk monitoring. AlbaCore’s maiden CLO will also incorporate AlbaCore’s unique investment process and focus on ESG as part of its credit selection criteria.

Deborah Cohen Malka, Managing Director and Deputy Portfolio Manager, added, “ESG is a critical element of our Firm’s values and investment process. We continue to enhance the manner in which we implement ESG as part of our bottom up credit selection process. We also value our partners’ input to understand and incorporate their ESG ideas so we can continue to be a dynamic leader in credit investing and ESG related issues.”

David Allen, Founder and Chief Investment Officer, concluded: “AlbaCore is delighted and grateful for the opportunity to create new partnerships and expand upon existing relationships as we mature as a firm. We have come a long way since our founding in 2016, and we would not be where we are without our partners. Looking ahead we feel well positioned to continue to deliver strong risk-adjusted returns in 2020. We have an active private market pipeline, and dry powder to be opportunistic as markets digest the recent UK election results and navigate what could be an unpredictable year leading up to the US elections in November. We look forward to active and continued engagement with our partners in the coming year.”

About AlbaCore Capital Group

AlbaCore is a specialist European credit platform focused on European corporate credit markets. Founded in 2016, AlbaCore manages €3.6bn5 of AUM for global pension funds, insurance companies, family offices and endowments. AlbaCore takes a patient, long-term investment approach to private and opportunistic European credit markets. The credit selection process is based on fundamental research with a focus on capital preservation, ESG factors and risk-adjusted returns. Headquartered in London with an office in Dublin, AlbaCore is an organisation built on values, with a partnership approach alongside our investors and counterparties at our core.

www.AlbaCoreCapitalGroup.com

____________________
1 AUM is calculated as the sum of the Net Asset Value, undrawn capital commitments and available debt finance for Fund II as of 31 December 2019.
2 AUM is calculated as the sum of the Net Asset Value, undrawn capital commitments and available debt finance of all vehicles managed by AlbaCore.
3 Gross Internal Rate of Return (“IRR”) is calculated using fully equalised cash flows between Fund II and an investor as if all current investors had been committed to Fund II from inception. Rate of return calculated does not include management or performance fees, which would be reflected in a net internal rate of return (that would be lower) actually received by investors. Gross IRR is net of fund level expenses (including the costs of any such subscription line facility), but gross of management fees and performance fees. Past performance is not indicative of future results, which may vary.
4 Alpha generation is based on the gross composite IRR of AlbaCore Partners I ICAV and Fund II from inception of each fund to 31 December 2019 vs the blended IRR, assuming an equal weighting, of BAML Euro High Yield Index and S&P Euro Lev Loans Index as benchmarks for the performance of relative European credit markets.
5 AUM is calculated as the sum of the Net Asset Value, undrawn capital commitments and available debt finance of all vehicles managed by AlbaCore.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Integrated Hubs for Green Chemistry Research Aim to Transform How Chemicals and Materials Are Designed12.11.2026 17:00:00 CET | Press release

International network will investigate fundamental principles for creating safer, higher-performing chemicals and materials The Gordon and Betty Moore Foundation today announced four Integrated Research Hubs to explore new frontiers in chemical design, from materials that respond to their surroundings to molecules designed for safety from the start. Bringing together global researchers across institutions and disciplines, the hubs will investigate fundamental principles that could enable new capabilities in chemicals and materials while improving performance and protecting human health and the environment. The research priorities emerged through extensive engagement with the scientific community to identify the questions that could transform what chemistry can achieve. Each hub will connect researchers across institutions around one of four green chemistry focus areas: Safer molecular design: Led by The George Washington University, this hub will combine artificial intelligence and qua

Roquette Highlights Scalable Excipient and Capsule Solutions for Regional and Global Pharmaceutical Markets at CPHI India 202612.11.2026 16:00:00 CET | Press release

Helping pharmaceutical manufacturers accelerate the journey from formulation to market through deep technical expertise, meaningful innovation, close collaboration and global capabilities Roquette, a global leader in plant-based ingredients and a leading provider of pharmaceutical excipients, will showcase its comprehensive portfolio of excipient and capsule solutions at CPHI India 2026, Hall 1, Booth 1I12 from November 23 to 25, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261112803410/en/ Meet Roquette at CPHI India 2026, Hall 1, Booth 1I12 At the event, Roquette will demonstrate how it helps pharmaceutical manufacturers accelerate the journey from formulation to market with confidence. By combining technical expertise, trusted quality, meaningful innovation and close collaboration, Roquette helps customers address formulation, scale-up and manufacturing challenges across a broad range of pharmaceutical application

Tigo Energy and Google Cloud Pair AI-Powered Tools for Solar Installers and Utilities12.11.2026 15:00:00 CET | Press release

The collaboration combines Tigo software with Google’s Gemini models on Google Cloud to help automate installer and utility operations for distributed energy portfolios. Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy software solutions, today announced a collaboration with Google Cloud to develop AI-enabled operational workflows for solar installers and distributed energy portfolios. By making core Tigo data and software products available through Google Cloud, Tigo aims to deliver faster deployment, simplified data integration, and additional insights with Gemini. The resulting workflows will help installers, asset managers, and energy operators more easily identify issues, prioritize actions, and automate routine operational tasks across growing fleets of distributed energy systems. As solar and storage portfolios expand, energy businesses are increasingly responsible for managing more sites, more system data, and more custo

Patsnap Releases State of Pharma Intelligence 2026 Report, Reveals Pharma's Cautious Embrace of AI in Decision-Making12.11.2026 15:00:00 CET | Press release

A new survey of 130 senior life sciences leaders on AI in pharma R&D and competitive intelligence finds that 92% can name a recent R&D, portfolio, or partnership decision where AI changed the outcome. Patsnap, the AI-native innovation intelligence company for IP and R&D teams, today released "State of Pharma Intelligence 2026: The Confidence to Act", a benchmark report on how pharma teams use and trust AI in R&D, competitive intelligence and business development decisions. The report draws on responses from 130 senior leaders at Director level or above across the United States, the United Kingdom, Germany, Switzerland, and France, spanning drug developers, CDMOs/CMOs, CROs, and consulting and professional services firms. The survey was fielded in August 2026 in partnership with NewtonX. Patsnap commissioned the research to understand how AI is influencing decisions across pharma R&D and business development, what builds confidence in its output, and where intelligence workflows fall sh

REPLY: the Board of Directors Approves the Quarterly Financial Report as of 30 September 202612.11.2026 14:41:00 CET | Press release

All economic indicators have substantially improved:Consolidated turnover of €1,987.9 million (1,819.8 as at 30 September 2025)EBITDA of €354.9 million (335.5 as at 30 September 2025)EBIT of €286.7 million (281.0 as at 30 September 2025)Pre-tax profit of €291.6 million (268.1 as at 30 September 2025)Positive Net Financial Position of €397.0 million. Today, the Board of Directors of Reply [EXM, STAR: REY] approved the results as at 30 September 2026. The Group's consolidated turnover in the first nine months of the year reached €1,987.9 million, an increase of 9.2% compared to €1,819.8 million recorded on 30 September 2025. The indicators for the period are positive. Consolidated EBITDA was €354.9 million, equal to 17.9% of the consolidated revenues. As of September 2025 EBITDA was €335.5 million. EBIT, from January to September, reached €286.7 million, equal to 14.4% of the consolidated revenues. The corresponding 2025 figure was €281.0 million. Pre-tax profit, from January to Septembe

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye